Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease – an update
- 1 April 2013
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Clinical Immunology
- Vol. 9 (4), 301-306
- https://doi.org/10.1586/eci.13.11
Abstract
Adhesion molecules play a key role in the pathogenetic mechanisms of inflammatory bowel disease (IBD), both in Crohn's disease (CD) and ulcerative colitis (UC). In the last decade, some progress has been made in understanding their key role in leukocyte trafficking control in terms of basic research, but evidence of clinical efficacy is lacking. In the last 2 years, new molecules directed against integrins and integrin receptors have been developed and investigated in clinical trials, showing that anti-α4β7 integrin agents can be effective and safe for the induction and maintenance of remission in active CD and UC. Preliminary data show that anti-MAdCAM, anti-β7 and anti-integrin receptor agents are not all effective in IBD. Such results open new perspectives on clinical management of IBD, and new directions in understanding the role of adhesion molecules and leukocyte recruitment both in CD and UC.Keywords
This publication has 24 references indexed in Scilit:
- The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised studyGut, 2011
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7Integrin Therapeutic Antibody in Development for Inflammatory Bowel DiseasesJournal of Pharmacology and Experimental Therapeutics, 2009
- S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled TrialGastroenterology, 2009
- 392 PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's DiseaseGastroenterology, 2009
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- Evaluation of Patients Treated with Natalizumab for Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2006
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Treatment of Ulcerative Colitis with a Humanized Antibody to the α4β7IntegrinNew England Journal of Medicine, 2005
- Therapeutic antagonists and conformational regulation of integrin functionNature Reviews Drug Discovery, 2003
- Natalizumab for Active Crohn's DiseaseNew England Journal of Medicine, 2003